Sona Nanotech CEO on breakthrough cancer therapy results - ICYMI

Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has reported promising first-in-human results for its targeted hyperthermia therapy (THT), showing tumor elimination in most treated patients with advanced melanoma who had stopped responding to standard immunotherapy. The findings mark a major milestone for the Halifax-based nanotechnology company as it transitions from preclinical research to clinical development. Proactive spoke with David Regan, CEO of Sona Nanotech, to discuss the study results, how the therapy ...